BioCentury | Jan 28, 2020
Distillery Therapeutics

Inhibiting CD36 to overcome resistance to Tykerb in HER2-positive breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting CD36, a fatty acid transporter, could treat HER2-positive breast cancer and sensitize tumors resistant to Tykerb lapatinib. In patients with HER2-positive breast cancer, CD36 protein levels were higher...
BC Extra | Dec 11, 2019
Clinical News

AstraZeneca, Daiichi’s trastuzumab ADC sets new efficacy bar in breast cancer

Trastuzumab deruxtecan from AstraZeneca and Daiichi Sankyo may have established a new threshold for efficacy in HER2+ breast cancer based on pivotal Phase II data. The data were better, in a sicker patient population, than...
BC Extra | Oct 21, 2019
Clinical News

Seattle Genetics at all-time high on strength of breast cancer readout

Seattle Genetics added more than $2 billion in market cap Monday after reporting pivotal survival data for breast cancer therapy tucatinib, a TKI targeting HER2 which is designed to have a favorable toxicity profile compared...
BC Innovations | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BC Extra | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
BC Innovations | Apr 18, 2019
Distillery Techniques

Patient cell-derived, 3-D model of PDAC and tumor microenvironment

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: 3-D models A patient cell-derived 3-D model of PDAC with active fluid motion could be used to screen therapies for the indication. Generation of the model involves: plating primary human...
BC Extra | Sep 14, 2018
Company News

ACS’s Brawley disappointed in Baselga resignation

American Cancer Society Chief Medical and Scientific Officer Otis Brawley said he was disappointed that José Baselga resigned from Memorial Sloan Kettering Cancer Center after failing to disclose financial ties to industry. Baselga, who was...
BC Week In Review | Aug 31, 2018
Clinical News

China approves Hengrui breast cancer drug on Phase II data

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China’s State Drug Administration conditionally approved pyrotinib (SHR-1258, HTI-1001) in combination with capecitabine to treat HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or...
BC Extra | Aug 22, 2018
Company News

China approves Hengrui breast cancer drug on Phase II data

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China’s State Drug Administration conditionally approved pyrotinib in combination with capecitabine to treat HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy....
BC Innovations | Mar 13, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PHLDA1 could help predict resistance to RTK inhibitors in endometrial, breast and other cancers. In tumor samples from patients with metastatic breast cancer or locally advanced non-metastatic renal cancer...
Items per page:
1 - 10 of 241